These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 25739318)

  • 1. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
    Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
    Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
    Cai L; Wang Z; Liu D
    Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
    Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
    BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer.
    Fang J; Zhang M; Li Q
    Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
    Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
    Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
    Amatangelo MD; Garipov A; Li H; Conejo-Garcia JR; Speicher DW; Zhang R
    Cell Cycle; 2013 Jul; 12(13):2113-9. PubMed ID: 23759589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
    Chen Q; Zheng PS; Yang WT
    Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer.
    Sun NX; Ye C; Zhao Q; Zhang Q; Xu C; Wang SB; Jin ZJ; Sun SH; Wang F; Li W
    PLoS One; 2014; 9(7):e100340. PubMed ID: 25007342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 Mediates the Regulation of S100A4 on E-cadherin Expression and the Proliferation, Migration of Gastric Cancer Cells.
    Liu S; Chen D; Shen W; Chen L; Yu A; Fu H; Sun K; Sun X
    Hepatogastroenterology; 2015 May; 62(139):737-41. PubMed ID: 26897964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells.
    Ying L; Yan F; Williams BR; Xu P; Li X; Zhao Y; Hu Y; Wang Y; Xu D; Dai J
    Clin Exp Pharmacol Physiol; 2018 Jan; 45(1):58-67. PubMed ID: 28925507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.
    Nolan KD; Franco OE; Hance MW; Hayward SW; Isaacs JS
    J Biol Chem; 2015 Mar; 290(13):8271-82. PubMed ID: 25670862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
    Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
    Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttranscriptional silencing of the lncRNA MALAT1 by miR-217 inhibits the epithelial-mesenchymal transition via enhancer of zeste homolog 2 in the malignant transformation of HBE cells induced by cigarette smoke extract.
    Lu L; Luo F; Liu Y; Liu X; Shi L; Lu X; Liu Q
    Toxicol Appl Pharmacol; 2015 Dec; 289(2):276-85. PubMed ID: 26415832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.
    Tong ZT; Cai MY; Wang XG; Kong LL; Mai SJ; Liu YH; Zhang HB; Liao YJ; Zheng F; Zhu W; Liu TH; Bian XW; Guan XY; Lin MC; Zeng MS; Zeng YX; Kung HF; Xie D
    Oncogene; 2012 Feb; 31(5):583-94. PubMed ID: 21685935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.
    Fujii S; Ochiai A
    Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
    Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
    Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.
    Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY
    J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.
    Xiong X; Zhang J; Liang W; Cao W; Qin S; Dai L; Ye D; Liu Z
    Int J Oncol; 2016 Aug; 49(2):623-8. PubMed ID: 27278257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
    Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
    Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.